Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention is directed to inhibitors of ubiquitin-specific protease 7 (USP7) useful in the treatment of diseases or disorders associated with USP7 enzymes.
• USP7 ubiquitin-specific protease 7
• the invention is concerned with compounds and compositions inhibiting USP7, methods of treating diseases or disorders associated with USP7, and methods of synthesis of these compounds.
• Ubiquitination is a post translational modification initially identified as a crucial component of proteasomal degradation in the ubiquitin proteasome system (UPS).
• Ub(s) Ubiquitin
• Ub(s) an 8.5 kDa highly conserved protein
• the molecular mechanisms by which the UPS acts are also varied, with different chain linkages of ubiquitination controlling protein turnover, enzymatic activity, subcellular localization, and protein-protein interactions of substrate proteins.
• Komander D., et. al. The emerging complexity of protein ubiquitination," Biochem. Soc. Trans. 37(Pt 5):937-53 (2009)
• Ubiquitin-specific protease 7 is a Ubiquitin Specific Protease (USP) family deubiquitinase (DUB) that was originally identified as an enzyme that interacted with virally- encoded proteins of the Herpes simplex virus and later the Epstein-Barr virus.
• Ubiquitin-specific protease 7 Ubiquitin Specific Protease (USP) family deubiquitinase (DUB) that was originally identified as an enzyme that interacted with virally- encoded proteins of the Herpes simplex virus and later the Epstein-Barr virus.
• Ubiquitin-specific protease Ubiquitin Specific Protease family deubiquitinase (DUB) that was originally identified as an enzyme that interacted with virally- encoded proteins of the Herpes simplex virus and later the Epstein-Barr virus.
• USPs Ubiquitin Specific Proteases
• DUB classes which are thought to generally regulate ubiquitin homeostasis or to be involved in pre-processing of linear ubiquitin chains
• USPs remove ubiquitin from specific targets. Given this substrate specificity combined with the numerous roles ubiquitination has in the cell, USPs are important regulators of a multitude of pathways, ranging from preventing the proteolysis of ubquitinated substrates, to controlling their nuclear localization.
• USP7 deubiquitinates a variety of cellular targets involved in different processes related to cancer and metastasis, neurodegenerative diseases, immunological disorders, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases.
• USP7 has been shown to stabilize D MT1, a DNA methyltransf erase that maintain epigenetic silencing, to maintain higher steady state-levels of Claspin, a protein involved in ataxia telangiectasia and Rad3-related (ATR) phosphorylation of Chkl, and to regulate Tip60 protein levels, a histone acetyltransferase and transcriptional coregulator involved in adipogenesis.
• USP7 In addition to regulating the protein stability of poly-ubiquitinated targets, USP7 also acts to control the subcellular localization of proteins. Mono-ubiquitination of PTEN has been shown to effect its cytoplasmic/nuclear partitioning, where nuclear localization of PTEN is important for its tumor suppression activity. (Trotman L.C., Wang X., Alimonti A., et al. "Ubiquitination regulates PTEN nuclear import and tumor suppression," Cell 128(1): 141-56 (2007); Song M.S., Salmena L., Carracedo A., et al.
• Cellular targets of USP7 also include the tumor suppressor p53 and its major E3 ligase, MDM2, stabilizing p53 via the degradation of MDM2.
• MDM2 major E3 ligase
• a first aspect of the invention relates to compounds of Formula (I):
• Xi is C, S, or S(O);
• X 2 is CR 7 or N
• Ri is H, D, -OH, -SH, - H 2 , - H(d-C 4 ) alkyl, -N((d-C 4 ) alkyl) 2 , or F;
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaiyl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - Ri 0 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ; each R 3 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, aryl, heteroaiyl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -CN, -OH, -C(0)Rn, .C(0)ORn, -OC(0)ORn, wherein
• R 3 together when on adjacent carbons form a (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R19; or two R 3 together form a (C 3 -C 8 ) spirocycloalkyl optionally substituted with one or more R19; or two R 3 together form a spiroheterocyclyl optionally substituted with one or more R i9 ; or two R 3 together when on adjacent carbons form an aryl ring optionally substituted with one or more R19; or two R 3 together when on adjacent carbons form an heteroaiyl ring optionally substituted with one or more R19;
• R4 is (Ci-C 6 ) alkyl, -(C 0 -C 3 ) alkylene-aryl, heteroaiyl, (C 3 -C 8 ) cycloalkyl, CD 3 or heterocyclyl, wherein aryl, heteroaiyl, heterocyclyl and cycloalkyl are optionally substituted with one or more Ri 2 ;
• R 5 and R 5 ' are independently H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, or halogen; or R-5 and R 5 ' together form a (C 3 -C 6 ) cycloalkyl or heterocyclyl ring optionally substituted with one or more substituents independently selected from halogen, -CN, (Ci-C 6 ) alkyl, -OH, -CH2OH, -(Co-C 2 )-alkylene-0(Ci-C 6 ) alkyl, or -(C 0 -C 2 )-alkylene-NRi7Ri8;
• Re is independently H, D, halogen, -CN, -NR17R18, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, or -OH when X 2 is N;
• R 7 is H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C C 6 ) alkoxy,
• each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• heterocyclyl ring optionally substituted with one or more R9;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rii, -NRi 0 C(O)Rn, - R 10 R 11 , -S(0) q Rio, -S(O) q NR 10 Rn, -NR 10 S(O) q R u , oxo, -P(0)((d-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more substituent
• each Rio and Rn is independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C 0 -C 3 ) alkylene-aryl, -(C 0 -C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl, -(C 0 -C4) alkylene-heterocyclyl, -(C 0 -C 4 ) alkylene-heteroaryl, or -CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more substituents independently selected from (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy,
• each R 12 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• Ri 3 together when on adjacent carbons form a heterocyclyl ring optionally substituted with one or more R1 ⁇ 2; or two Ri 3 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R i6 ; or two R i3 together with the carbon to which they are attached can form a spiroheterocyclyl optionally substituted with one or more R1 ⁇ 2;
• each Ri and R 15 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl,
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each Ri 7 and R i8 is at each occurrence independently H or (Ci-C 6 ) alkyl
• Ri 9 is independently at each occurrence H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl,
• n 0, 1 or 2;
• n 0, 1, 2 or 3;
• p 0, 1, or 2;
• each q is 0, 1, or 2.
• Another aspect of the invention relates to a method of treating a disease or disorder associated with modulation of USP7.
• the method comprises administering to a patient in need of a treatment for diseases or disorders associated with modulation of USP7 an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• Another aspect of the invention is directed to a method of inhibiting USP7.
• the method involves administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• Another aspect of the invention relates to a method of treating cancer.
• the method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• Another aspect of the invention relates to a method of treating a neurodegenerative disease.
• the method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• Another aspect of the invention relates to a method of treating a viral infection or disease.
• the method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• Another aspect of the invention relates to a method of treating an inflammatory disease or condition.
• the method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• Another aspect of the invention relates to a method of inducing cell cycle arrest, apoptosis in tumor cells and/or enhanced tumor-specific T-cell immunity.
• the method comprises contacting the cells with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable carrier.
• the pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
• Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease associated with inhibiting USP7.
• Another aspect of the present invention relates to the use of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the treatment of a disease associated with inhibiting USP7.
• the present invention further provides methods of treating a disease or disorder associated with modulation of USP7 including, cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases, comprising administering to a patient suffering from at least one of said diseases or disorder a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• a disease or disorder associated with modulation of USP7 including, cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases.
• the present invention provides inhibitors of USP7 that are therapeutic agents in the treatment of diseases such as cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases.
• diseases such as cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases.
• the present invention further provides compounds and compositions with an improved efficacy and safety profile relative to known USP7 inhibitors.
• the present disclosure also provides agents with novel mechanisms of action toward USP7 enzymes in the treatment of various types of diseases including cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases.
• the present invention provides the medical community with a novel pharmacological strategy for the treatment of diseases and disorders associated with USP7 enzymes.
• the present invention relates to compounds and compositions that are capable of inhibiting the activity USP7.
• the invention features methods of treating, preventing or ameliorating a disease or disorder in which USP7 plays a role by administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• the methods of the present invention can be used in the treatment of a variety of USP7 dependent diseases and disorders by inhibiting the activity of USP7 enzymes.
• USP7 provides a novel approach to the treatment, prevention, or amelioration of diseases including, but not limited to, cancer and metastasis, neurodegenerative diseases, immunological disorders, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases.
• diseases including, but not limited to, cancer and metastasis, neurodegenerative diseases, immunological disorders, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases.
• an alkyl group can (but is not required to) be bonded other substituents (e.g., heteroatoms).
• substituents e.g., heteroatoms
• an alkyl group that is optionally substituted can be a fully saturated alkyl chain (i.e. , a pure hydrocarbon).
• the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bounded to a halogen atom, a hydroxyl group, or any other substituent described herein.
• substituents used in the optional substitution of the described groups include, without limitation, halogen, oxo, -OH, -CN, -COOH, -CH 2 CN, -0-(d-C 6 ) alkyl, (Ci-C 6 ) alkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkyl, Ci-C 6 haloalkoxy, -0-(C 2 -C 6 ) alkenyl, -0-(C 2 -C 6 ) alkynyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -OH, -OP(0)(OH) 2 , -OC(0)(C C 6 ) alkyl, -C(0)(d-C 6 ) alkyl, -OC(0)0(Ci
• substituted means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions.
• an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.
• aryl refers to cyclic, aromatic hydrocarbon groups that have 1 to 3 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl). The aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment.
• substituents include, but are not limited to, - H, -halogen, -0-(Ci-C 6 ) alkyl, (Ci-C 6 ) alkyl, -0-(C 2 -C 6 ) alkenyl, -0-(C 2 -C 6 ) alkynyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -OH, -OP(0)(OH) 2 , -OC(0)(Ci-C 6 ) alkyl, -C(0)(Ci-C 6 ) alkyl, - OC(0)0(Ci-C 6 ) alkyl, H 2 , H((Ci-C 6 ) alkyl), N((Ci-C 6 ) alkyl)3 ⁇ 4 -S(0) 2 -(Ci-C 6 ) alkyl, - S(0) H(Ci-C 6 ) alkyl, and S(0)N((d
• aryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully saturated ring.
• Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.
• heteroaryl means a monovalent monocyclic aromatic radical of 5 to 24 ring atoms or a polycyclic aromatic radical, containing one or more ring heteroatoms selected from N, O, or S, the remaining ring atoms being C.
• Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, O, or S.
• the aromatic radical is optionally substituted independently with one or more substituents described herein.
• Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[l,2-b]pyrazolyl, furo[2,3- c]pyridinyl, imidazo[l,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]
• heteroaryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully saturated ring.
• exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4- dihydro-lH ⁇ isoquinolinyl, 2,3 -dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl.
• Halogen or "halo" refers to fluorine, chlorine, bromine, or iodine.
• Alkyl refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms.
• Examples of a (Ci-C 6 ) alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
• Alkoxy refers to a straight or branched chain saturated hydrocarbon containing 1- 12 carbon atoms containing a terminal "O" in the chain, i.e., -O(alkyl).
• alkoxy groups include without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.
• alkenyl refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms.
• the "alkenyl” group contains at least one double bond in the chain.
• the double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group.
• alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl.
• An alkenyl group can be unsubstituted or substituted.
• Alkenyl, as herein defined may be straight or branched.
• Alkynyl refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms.
• the "alkynyl” group contains at least one triple bond in the chain.
• alkenyl groups include ethynyl, propargyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl.
• An alkynyl group can be unsubstituted or substituted.
• alkylene or "alkylenyl” refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. As herein defined, alkylene may also be a Ci-C 6 alkylene. An alkylene may further be a C 1 -C4 alkylene.
• Typical alkylene groups include, but are not limited to, -CH 2 -, - CH(CH 3 )-, -C(CH 3 ) 2 -, -CH 2 CH 2 -, -CH 2 CH(CH 3 )-, -CH 2 C(CH 3 ) 2 -, -CH 2 CH 2 CH 2 -, - CH 2 CH 2 CH 2 CH 2 -, and the like.
• Cycloalkyl means monocyclic saturated carbon rings containing 3-18 carbon atoms.
• Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl.
• Cycloalkylalkyl means monocyclic saturated carbon rings containing 3-24 carbon atoms further substituted with (Ci-C 6 ) alkyl groups. In general cycloalkylalkyl groups herein
• n is an integer from 1 to 16.
• the cycloalkyl ring or carbocycle may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment.
• the substituents can themselves be optionally substituted.
• cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, bicyclo[2.2.2]octenyl, decahydronaphthalenyl, octahydro-lH-indenyl, cyclopentenyl, cyclohexenyl, cyclohexa-l,4-dienyl, cyclohexa-1,3- dienyl, 1,2,3,4-tetrahydronaphthalenyl, octahydropentalenyl, 3a,4,5,6,7,7a-hexahydro-lH- indenyl, 1,2,3, 3a-tetrahydropentalenyl, bicyclo[3.1.0]hexanyl, bicyclo[2,
• Heterocyclyl or “heterocycloalkyl” monocyclic rings containing carbon and heteroatoms taken from oxygen, nitrogen, or sulfur and wherein there is not delocalized ⁇ electrons (aromaticity) shared among the ring carbon or heteroatoms.
• the heterocycloalkyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted.
• heterocyclyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, and homotropanyl.
• hydroxyalkyl means an alkyl group as defined above, where the alkyl group is substituted with one or more OH groups.
• hydroxyalkyl groups include HO- CH 2 -, HO-CH 2 -CH 2 - and CH 3 -CH(OH)-.
• haloalkyl refers to an alkyl group, as defined herein, which is substituted one or more halogen. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.
• haloalkoxy refers to an alkoxy group, as defined herein, which is substituted one or more halogen.
• haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.
• cyano as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond, i.e., C ⁇ N.
• amine refers to primary (R- H 2 , R ⁇ H), secondary (R 2 - H, R 2 ⁇ H) and tertiary (R 3 -N, R ⁇ H) amines.
• a substituted amine is intended to mean an amine where at least one of the hydrogen atoms has been replaced by the substituent.
• amino as used herein means a substituent containing at least one nitrogen atom. Specifically, H 2 , -NH(alkyl) or alkylamino, -N(alkyl) 2 or dialkylamino, amide-, carbamide-, urea, and sulfamide substituents are included in the term "amino".
• dialkylamino refers to an amino or H 2 group where both of the hydrogens have been replaced with alkyl groups, as defined herein above, i.e., -N(alkyl) 2 .
• alkyl groups on the amino group can be the same or different alkyl groups.
• alkylamino groups include, but are not limited to, dimethylamino (z.e.,-N(CH 3 ) 2 ), diethylamino, dipropylamino, diiso-propylamino, di-n-butylamino, di-sec-butylamino, di-tert-butylamino, methyl(ethyl)amino, methyl(butylamino), etc.
• Spirocycloalkyl or "spirocyclyl” means carbogenic bicyclic ring systems with both rings connected through a single atom.
• the ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spriohexane, spiroheptane, spirooctane, spirononane, or spirodecane.
• One or both of the rings in a spirocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
• a (C 3 -C 12 ) spirocycloalkyl is a spirocycle containing between 3 and 12 carbon atoms.
• One or more of the carbon atoms can be substituted with a heteroatom.
• the term "spiroheterocycloalkyl" or “spiroheterocyclyl” is understood to mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl).
• solvate refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.
• the term "isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of Formula (I) may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers.
• compositions comprising an effective amount of a disclosed compound and a pharmaceutically acceptable carrier.
• pharmaceutically acceptable salts include, e.g., water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumerate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxyna
• a "patient” or “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
• an "effective amount" when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.
• carrier encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
• treating refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.
• disorder is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
• administer refers to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.
• prodrug means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound.
• the present invention relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, capable of inhibiting USP7, which are useful for the treatment of diseases and disorders associated with modulation of a USP7 enzyme.
• the invention further relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, which are useful for inhibiting USP7.
• the compounds of Formula (I) have the structure of Formula (la): N
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - Ri 0 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ;
• R4 is (Ci-C 6 ) alkyl, -(C 0 -C 3 ) alkylene-aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, CD 3 , or heterocyclyl, wherein aryl, heteroaryl, heterocyclyl and cycloalkyl are optionally substituted with one or more R12;
• R 5 is H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy,
• Re is independently H, D, halogen, -CN, -NR n Ri 8 , (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, or -OH; each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O) Ri 0 Rn, - Ri 0 C(O)Rn, - RioRn, -S(0) q Rio, -S(O) q Ri 0 Rn, - Ri 0 S(O) q Rn, oxo, -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl, halogen, aryl, -OH, -
• each Ri 3 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• Ri and R15 together form a heterocyclyl ring optionally substituted with one or more
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkoxy, -C(0)(Ci-C 3 ) alkyl, -NHC(0)(Ci-C 4 ) alkyl, -CN, -CH 2 CN, -CRioRnNRioRii, oxo, -NRioRii,
• each Ri7 and Ri 8 is independently at each occurrence H or (Ci-C 6 ) alkyl; p is 0, 1, or 2; and each q is 0, 1, or 2.
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - Ri 0 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ;
• R4 is (Ci-C 6 ) alkyl, -(C 0 -C 3 ) alkylene-aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, CD 3 , or heterocyclyl, wherein aryl, heteroaryl, heterocyclyl and cycloalkyl are optionally substituted with one or more R12;
• R 5 is H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy,
• Re is independently H, D, halogen, -CN, - R n Ri 8 , (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, or -OH when X 2 is N;
• R 7 is H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy,
• each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• heterocyclyl ring optionally substituted with one or more R9;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rii, -NRi 0 C(O)Rn, - R10R11, -S(0) q Rio, -S(O) q NR 10 Rn, -NR 10 S(O) q R u , oxo, -P(0)((d-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more substituents
• each R 12 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each R i3 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each Ri4 and R15 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl,
• alkylene-heterocyclyl -(C 0 -C 4 ) alkylene-aryl, -(C 0 -C 4 ) alkylene-heteroaryl, or -CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more R 16 ;
• Ri4 and R15 together form a heterocyclyl ring optionally substituted with one or more
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkoxy, -C(0)(Ci-C 3 ) alkyl, - HC(0)(d-C 4 ) alkyl, -CN, -CH 2 CN, -CR10R11NR10R11, oxo, -NRi 0 Rn,
• each Ri7 and Ri 8 is at each occurrence independently H or (Ci-C 6 ) alkyl; p is 0, 1, or 2; and each q is 0, 1, or 2.
• the compounds of Formula (I) have the structure of Formula (Ic):
• Xi is C, S, or S(O); Y is CH or N;
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ; each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• heterocyclyl ring optionally substituted with one or more R9;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rn, -NRi 0 C(O)Rn, -NR10R11, -S(0) q Rio, -S(O) q NRi 0 Rn, -NRi 0 S(O) q Rn, oxo, -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more
• each R 12 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each R i3 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each Ri and R 15 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl,
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• Ri 6 when on adjacent carbons form an aryl ring
• R 1 ⁇ 2 together when on adjacent carbons form a spiroheterocyclyl ring
• p is 0, 1, or 2
• each q is 0, 1, or 2
• r is 1, 2, 3, 4, or 5.
• the compounds of Formula (I) have the structure of Formula (Id):
• Xi is C, S, or S(O); Y is CH or N;
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - Ri 0 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ; each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• heterocyclyl ring optionally substituted with one or more R 9 ;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rn, -NRi 0 C(O)Rn, -NR10R11, -S(0) q Rio, -S(O) q NRi 0 Rn, -NRi 0 S(O) q Rn, oxo, -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more
• each Rio and Rn is independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C 0 -C 3 ) alkylene-aryl, -(C 0 -C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl, -(C 0 -C 4 ) alkylene-heterocyclyl, -(C 0 -C 4 ) alkylene-heteroaryl, or -CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycl
• each Ri 3 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• Ri 4 C(0)Ri5, -OH, -CN, -C(0)Ri 4 , or -NRi 4 Ri 5 ; or two Ri 3 together when on adjacent carbons form a heterocyclyl ring optionally substituted with one or more R1 ⁇ 2; or two Ri 3 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R i6 ; or two R i3 together with the carbon to which they are attached can form a spiroheterocyclyl optionally substituted with one or more R1 ⁇ 2;
• each Ri and R 15 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C1-C4) alkylene-(C 3 -C 8 ) cycloalkyl,
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• Ri6 when on adjacent carbons form an aryl ring
• R 1 ⁇ 2 when on adjacent carbons form a spiroheterocyclyl ring
• p is 0, 1, or 2
• each q is 0, 1, or 2
• r is 1, 2, 3, 4, or 5.
• Xi is C, S, or S(O);
• Ri is H, D, -OH, -SH, - H 2 , - H(d-C 4 ) alkyl, -N((d-C 4 ) alkyl) 2 , or F;
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NRioRn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ;
• R 5 and R 5 ' are independently H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, or halogen; or
• Re is independently H, D, halogen, -CN, -NRnRis, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, or -OH when X 2 is N; each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• heterocyclyl ring optionally substituted with one or more R 9 ;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rii, -NRi 0 C(O)Rn, -NR10R11, -S(0) q Rio, -S(O) q NRi 0 Rn, -NRi 0 S(O) q Rn, oxo, -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more
• each Rio and Rn is independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C 0 -C 3 ) alkylene-aryl, -(C 0 -C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl, -(C 0 -C 4 ) alkylene-heterocyclyl, -(C 0 -C 4 ) alkylene-heteroaryl, or -CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycl
• each Ri 4 and R15 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C1-C4) alkylene-(C 3 -C 8 ) cycloalkyl,
• alkylene-heterocyclyl -(C 0 -C 4 ) alkylene-aryl, -(C 0 -C 4 ) alkylene-heteroaryl, or -CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more R 16 ;
• Ri 4 and R15 together form a heterocyclyl ring optionally substituted with one or more
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each Rn and Ri 8 is at each occurrence independently H or (Ci-C 6 ) alkyl; p is 0, 1, or 2; and each q is 0, 1, or 2.
• the compounds of Formula (I) have the structure of Formula (If):
• Xi is C, S, or S(O);
• Ri is H, D, -OH, -SH, - H 2 , -NH(Ci-C 4 ) alkyl, -N((Ci-C 4 ) alkyl) 2 , or F;
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ;
• R 5 and R 5 > are independently H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, or halogen; or
• R 5 and R 5 ' together form a (C 3 -C 6 ) cycloalkyl or heterocyclyl ring optionally substituted with one or more substituents independently selected from halogen, -CN,
• Re is independently H, D, halogen, -CN, -NR n Ri 8 , (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, or -OH when X 2 is N; each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• heterocyclyl ring optionally substituted with one or more R9;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rii, -NRi 0 C(O)Rn, - R10R11, -S(0) q Rio, -S(O) q NR 10 Rn, -NR 10 S(O) q R u , oxo, -P(0)((d-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more substituents
• each Rio and Ru is independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C2-C 6 ) alkenyl, (C2-C 6 ) alkynyl, -(Co-C 3 ) alkylene-aryl, -(Co-C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl, -(Co-C 4 ) alkylene-heterocyclyl, -(Co-C 4 ) alkylene-heteroaryl, or -CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with
• each Ri and R15 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C1-C4) alkylene-(C 3 -C 8 ) cycloalkyl,
• alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more R 16 ;
• Ri and R15 together form a heterocyclyl ring optionally substituted with one or more
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each Ri7 and Ri 8 is at each occurrence independently H or (Ci-C 6 ) alkyl; p is 0, 1, or 2; and each q is 0, 1, or 2.
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ;
• R4 is (Ci-C 6 ) alkyl, -(C 0 -C 3 ) alkylene-aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, CD 3 , or heterocyclyl, wherein aryl, heteroaryl, heterocyclyl and cycloalkyl are optionally substituted with one or more R i2 ; each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• alkyl, alkylene, aryl, heteroaryl, and heterocyclyl are optionally substituted with one or more R 9 ; or two R 8 together when on adjacent carbons form an aryl ring optionally substituted with one or more R 9 ; or two R 8 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R9; or two R 8 together when on adjacent carbons form a
• heterocyclyl ring optionally substituted with one or more R 9 ;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O) Ri 0 Rn, - Ri 0 C(O)Rn, - R10R11, -S(0) q Rio, -S(O) q Ri 0 Rn, - Ri 0 S(O) q Rn, oxo, -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more substituents independently selected
• each Ri 3 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) alkoxy, halogen, (Ci-C 6 ) haloalkoxy, (Ci-C 6 ) hydroxyalkyl, heterocyclyl, heteroaryl, aryl, -OR 14 , -C(0)Ri 4 , -C(0) Ri 4 Ri 5 , - Ri 4 Ri 5 , -S(0) q Ri 4 ,
• Ri 4 C(0)Ri 5 , -OH, -CN, -C(0)Ri 4 , or -NRi 4 Ri 5 ; or two Ri 3 together when on adjacent carbons form a heterocyclyl ring optionally substituted with one or more R1 ⁇ 2; or two R 13 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R1 ⁇ 2; or two R 13 together with the carbon to which they are attached can form a spiroheterocyclyl optionally substituted with one or more R1 ⁇ 2;
• each Ri and R 15 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C1-C4) alkylene-(C 3 -C 8 ) cycloalkyl,
• alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more R 16 ;
• Ri and R 15 together form a heterocyclyl ring optionally substituted with one or more
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• Ri 6 when on adjacent carbons form an aryl ring; or two R 1 ⁇ 2 together when on adjacent carbons form a spiroheterocyclyl ring; p is 0, 1, or 2; and each q is 0, 1, or 2.
• the compounds of Formula (I) have the structure of Formula (Ih):
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - Ri 0 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ;
• R4 is (Ci-C 6 ) alkyl, -(C 0 -C 3 ) alkylene-aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, CD 3 , or heterocyclyl, wherein aryl, heteroaryl, heterocyclyl and cycloalkyl are optionally substituted with one or more R i2 ; each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• heterocyclyl ring optionally substituted with one or more R9;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rn, -NRi 0 C(O)Rn, -NR10R11, -S(0) q Rio, -S(O) q NRi 0 Rn, -NRi 0 S(O) q Rn, oxo, -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more
• each Rio and Ru is independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(Co-C 3 ) alkylene-aryl, -(Co-C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl, -(Co-C 4 ) alkylene-heterocyclyl, -(Co-C 4 ) alkylene-heteroaryl, or -CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optional
• each Ri 3 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each Ri 4 and R 15 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C1-C4) alkylene-(C 3 -C 8 ) cycloalkyl,
• alkylene-heterocyclyl -(C 0 -C 4 ) alkylene-aryl, -(C 0 -C 4 ) alkylene-heteroaryl, or -CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more R 16 ;
• Ri 4 and R 15 together form a heterocyclyl ring optionally substituted with one or more
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• Ri 6 when on adjacent carbons form an aryl ring; or two R 1 ⁇ 2 together when on adjacent carbons form a spiroheterocyclyl ring; p is 0, 1, or 2; and each q is 0, 1, or 2.
• Y is CH or N
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - Ri 0 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ; each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• heterocyclyl ring optionally substituted with one or more R 9 ;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rn, -NRi 0 C(O)Rn, -NR10R11, -S(0) q Rio, -S(O) q NRi 0 Rn, -NRi 0 S(O) q Rn, oxo, -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more
• each R 12 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each R i3 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• each Ri and R 15 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl,
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• Ri 6 when on adjacent carbons form an aryl ring
• R 1 ⁇ 2 together when on adjacent carbons form a spiroheterocyclyl ring
• p is 0, 1, or 2
• each q is 0, 1, or 2
• r is O, 1, 2, 3, 4, or 5.
• Y is CH or N
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 ; each R 8 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, -(Ci-C 3 )-alkylene-0(Ci-C 6 ) alkyl, -(C 0 -C 4 )-alkylene-aryl, -(C 0 -C 4 )-alkylene-heteroaryl, (C 3 -C 10 ) cycloalkyl, heterocyclyl,
• heterocyclyl ring optionally substituted with one or more R9;
• each R 9 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rn, -NRi 0 C(O)Rn, - R10R11, -S(0) q Rio, -S(O) q NR 10 Rn, -NR 10 S(O) q R u , oxo, -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, CN, or -O-heteroaiyl, wherein alkyl, aryl, and cycloalkyl are optionally substituted with one or more substituent
• each Rio and Rn is independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C 0 -C 3 ) alkylene-aryl, -(C 0 -C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl, -(C 0 -C4) alkylene-heterocyclyl, -(C 0 -C 4 ) alkylene-heteroaryl, or -CN, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl
• each Ri 2 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (C 3 -C 8 ) cycloalkyl, aryl, heteroaryl, -O-aiyl,
• Ri 4 Ri5 -C(0) Ri 4 Ri5, -S(0) q Ri 4 Ri5, - Ri 4 Ri 5 , - Ri 4 C(0) Ri 4 Ri 5 , - Ri 4 C(O)ORi 0 , - Ri 4 SO q Ri 0 , - Ri 4 CORio, halogen, -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 or -OH, wherein alkyl, aryl, heteroaryl, and cycloalkyl are optionally substituted with one or more Ri 3 ;
• each R i3 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• Ri 4 C(0)Ri5, -OH, -CN, -C(0)Ri 4 , or -NRi 4 Ri 5 ; or two Ri 3 together when on adjacent carbons form a heterocyclyl ring optionally substituted with one or more R i6 ; or two R i3 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more R1 ⁇ 2; or two Ri 3 together with the carbon to which they are attached can form a spiroheterocyclyl optionally substituted with one or more R1 ⁇ 2;
• each R i4 and Ri 5 are independently at each occurrence selected from H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl,
• R i4 and Ri 5 together form a heterocyclyl ring optionally substituted with one or more
• each Ri 6 is independently at each occurrence selected from D, (Ci-C 6 ) alkyl,
• X 1 is C, S, or S(O). In another embodiment, X 1 is C. In yet another embodiment, X 1 is S. In another embodiment, X 1 is S(O).
• X 2 is N. In another embodiment, X 2 is CR 7 .
• Ri is H, D, -OH, -SH, - H 2 , -NH(C 1 - C 4 ) alkyl, -N((Ci-C 4 ) alkyl) 2 , or F.
• Ri is -OH, -SH, - H 2 ,
• Ri is -OH, -SH, - H 2 , - HCH 3 , -NHCH 2 CH 3 , -N(CH 3 ) 2 , -N(CH 2 CH 3 ) 2 or F.
• Ri is -OH, - H 2 , - HCH 3 , -N(CH 3 ) 2 , or F.
• R x is -OH, - H 2 , or F.
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or ORio.
• alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 .
• R 3 is D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, aryl, heteroaryl,
• R 3 is selected from (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, or -OH.
• R 3 is selected from (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl,
• R 3 is selected from (Ci-C 3 ) alkyl, (Ci-C 3 ) alkoxy, (Ci-C 3 ) haloalkyl, (Ci-C 3 ) haloalkoxy, or -OH.
• R 3 is selected from (Ci-C 3 ) alkyl, (Ci-C 3 ) alkoxy, or -OH.
• R 3 is selected from methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, or -OH.
• two R 3 together when on adjacent carbons can form a (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 19 .
• two R 3 together when on adjacent carbons can form a (C 3 -C 8 ) spirocycloalkyl optionally substituted with one or more R19.
• two R 3 together when on adjacent carbons can form a spiroheterocyclyl optionally substituted with one or more R 19 .
• two R 3 together when on adjacent carbons can form an aryl ring optionally substituted with one or more R 19 .
• two R 3 together when on adjacent carbons can form a heteroaryl ring optionally substituted with one or more R 19 .
• R4 is (Ci-C 6 ) alkyl
• R 5 is H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, or halogen.
• R 5 is H, D, (Ci-C 3 ) alkyl, (C 2 -C 3 ) alkenyl, (C 2 -C 3 ) alkynyl, (Ci-C 3 ) alkoxy, (Ci-C 3 ) haloalkyl, (Ci-C 3 ) haloalkoxy, or halogen.
• R 5 is H, D, (Ci-C 3 ) alkyl, (C 2 -C 3 ) alkenyl, (C 2 -C 3 ) alkynyl, (Ci-C 3 ) alkoxy, (Ci-C 3 ) haloalkyl, (Ci-C 3 ) haloalkoxy, or halogen.
• R 5 is H, D, (Ci-C 3 ) alkyl, (C 2 -C 3 ) alkenyl, (C 2 -C 3 ) alkynyl, (Ci-C 3 ) alkoxy,
• R 5 is H or (Ci-C 3 ) alkyl. In yet another embodiment, R 5 is H, methyl, ethyl, propyl, or isopropyl.
• R 5 > is H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, or halogen.
• R 5 > is H, D, (Ci-C 3 ) alkyl, (C 2 -C 3 ) alkenyl, (C 2 -C 3 ) alkynyl, (Ci-C 3 ) alkoxy, (Ci-C 3 ) haloalkyl, (Ci-C 3 ) haloalkoxy, or halogen.
• R 5 > is H, D, (Ci-C 3 ) alkyl, (Ci-C 3 ) alkoxy, (Ci-C 3 ) haloalkyl, or halogen.
• R 5 > is H or (Ci-C 3 ) alkyl.
• R 5 > is H, methyl, ethyl, propyl, or isopropyl.
• R 5 and R 5 ' together can form a
• the optional substituents can be halogen, -CN, (Ci-C 6 ) alkyl, -OH, -CH 2 OH, -(C 0 -C 2 )-alkylene-O(Ci-C 6 ) alkyl, or
• 5 is H, D, halogen, -CN, -NRi 7 Ri 8 , (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, or -OH.
• R 6 is H, D, halogen, -CN, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, or -OH.
• 5 is H, halogen, or
• R6 is H, F, CI, methyl, ethyl, propyl, or isopropyl.
• R 7 is H, D, (Ci-C 6 ) alkyl,
• R 7 is H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, halogen, optionally substituted aryl, optionally substituted heteroaryl, -CN, or -NRioRn.
• R 7 is H, D, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (Ci-C 6 ) alkoxy,
• R 7 is H, D,
• (C1-C3) alkyl (C 2 -C 3 ) alkenyl, (C 2 -C 3 ) alkynyl, (C C 3 ) alkoxy, (C1-C3) haloalkyl,
• R 7 is H, D, (Ci-C 3 ) alkyl,
• R 7 is H, D, (Ci-C 3 ) alkyl, (Ci-C 3 ) alkoxy, (Ci-C 3 ) haloalkyl, or halogen.
• R 7 is H, D, (Ci-C 3 ) alkyl, (Ci-C 3 ) alkoxy, (Ci-C 3 ) haloalkyl, or halogen.
• R 7 is H, (Ci-C 3 ) alkyl, or halogen. In yet another embodiment, R 7 is H, methyl, ethyl, propyl, isopropyl, F or CI. In another embodiment, R 7 is H or methyl.
• R 8 is D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, -(Ci-C 3 )-alkylene-0(Ci-C 6 ) alkyl, -(Co-C 4 )-alkylene-aryl, -(Co-C 4 )-alkylene-heteroaryl, (C 3 -C 10 ) cycloalkyl, heterocyclyl, -(C 0 -C 4 )-alkylene-O-aryl,
• alkyl, alkylene, aryl, heteroaryl, and heterocyclyl can be optionally substituted with one or more R 9 .
• two R 8 together when on adjacent carbons can form an aryl ring optionally substituted with one or more R9.
• two R 8 together when on adjacent carbons can form a heteroaryl ring optionally substituted with one or more R 9 .
• two R 8 together when on adjacent carbons can form a heterocyclyl ring optionally substituted with one or more R9.
• R9 is D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (C 3 -C 8 ) cycloalkyl, halogen, aryl, -OH, -CN, -C(O)Ri 0 , -C(O)NRi 0 Rn, -NRi 0 C(O)Rn, -NRioRn, -S(O) q R 10 , -S(O) q NR 10 Rn, -NR 10 S(O) q R u , oxo, -P(0)((d-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 , -O-aiyl, or -O-heteroaiyl.
• the alkyl, aryl, and cycloalkyl are optionally substituted with one or more substituents independently selected from (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, halogen, aryl, -NRi 4 C(0)Ri 5 , -NRi 4 S(0) q Ri 5 , -OH or -CN.
• two Rg together when on adjacent carbons can form an aryl ring.
• two R 9 together when on adjacent carbons can form a heteroaryl ring.
• two R9 together when on adjacent carbons can form a (C 3 -C 10 ) cycloalkyl ring.
• Rio is H, (Ci-C 6 ) alkyl
• alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more substituents independently selected from (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, (C 3 -C 8 ) cycloalkyl, heterocyclyl, aryl, -S(0) q (Ci-C 3 ) alkyl,
• Rn is H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(C 0 -C 3 ) alkylene-aryl, -(C 0 -C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl,
• alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more substituents independently selected from (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) haloalkoxy, (C 3 -C 8 ) cycloalkyl, heterocyclyl, aryl, -S(0) q (Ci-C 3 ) alkyl,
• Rio and Rn together when on adjacent carbons can form a heterocyclyl ring optionally substituted with one or more substituents selected from oxo, -C(0)(Ci-C 3 ) alkyl or -NRi 4 NRi 5 .
• Ri 2 is selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) alkoxy, (Ci-C 6 ) haloalkyl, (C 3 -C 8 ) cycloalkyl, aryl, heteroaryl, -O-aiyl,
• R i3 is selected from D, (Ci-C 6 ) alkyl, (Ci-C 6 ) haloalkyl, (Ci-C 6 ) alkoxy, halogen, (Ci-C 6 ) haloalkoxy, (Ci-C 6 ) hydroxyalkyl, heterocyclyl, heteroaryl, aryl, -ORi 4 , -C(0)Ri4, -C(0)NRi 4 Ri5, -NR14R15, -S(0) q Ri 4 , -NRi 4 S(0) q Ri 5 , -S(0) q NRi 4 Ri 5 , - Ri 4 C(0) Ri 4 Ri 5 , - Ri 4 C(0)ORi 5 , -P(0)((Ci-C 6 )alkyl) 2 , -P(0)(aryl) 2 , -SiMe 3 , SF 5 or -CN, wherein alkyl, cycloalkyl, ary
• two Ri 3 together when on adjacent carbons form a heterocyclyl ring optionally substituted with one or more Ri 6 .
• two Ri 3 together when on adjacent carbons form a heteroaryl ring optionally substituted with one or more Ri 6 .
• two Ri 3 together with the carbon to which they are attached can form a spiroheterocyclyl optionally substituted with one or more Ri 6 .
• R i4 is H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl,
• Ri 5 is H, (Ci-C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -(Ci-C 4 ) alkylene-(C 3 -C 8 ) cycloalkyl,
• R i and Ri 5 together can form a heterocyclyl ring optionally substituted with one or more Ri 6 .
• R1 ⁇ 2 is D, (Ci-C 6 ) alkyl
• two R i6 together when on adjacent carbons can form an aryl ring.
• two R 1 ⁇ 2 together when on adjacent carbons can form a spiroheterocyclyl ring.
• Rn is H or (Ci-C 6 ) alkyl. In another embodiment, Rn is independently H or (Ci-C 4 ) alkyl. In yet another embodiment, Rn is independently H, methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, or tert-butyl.
• Ri 8 is H or (Ci-C 6 ) alkyl. In another embodiment, R i8 is independently H, methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, or tert- butyl.
• R19 is H, D, (Ci-C 6 ) alkyl
• n is 0, 1 or 2. In another embodiment, m is 0 or 1.
• n is 0, 1, 2 or 3. In another embodiment, n is 0, 1, or 2. In another embodiment, n is 1.
• p is 0. In another embodiment, p is 1. In yet another embodiment, p is 2.
• q is 0. In another embodiment, q is 1. In yet another embodiment, q is 2.
• X 1 is C. In another embodiment, X 1 is C and X 2 is N. In yet another embodiment, X 1 is C, X 2 is N and Ri is OH. In another embodiment, X 1 is C, X 2 is N, Ri is OH, and R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - R 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 .
• Xi is C
• X 2 is N
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -OR10, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H.
• X 1 is C
• X 2 is N
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - R 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 ' is H.
• X 1 is C
• X 2 is N
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• R6 is H.
• Xi is C
• X 2 is N
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• R 6 is H
• R4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more R12.
• X 1 is C
• X 2 is N
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -OR10, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• 5 is H
• R4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more R12
• R12 is (Ci-C 6 ) alkyl, (Ci-C 6 ) haloalkyl, halogen, -O-aiyl, or -O- heteroaryl optionally substituted with one or more R i3 .
• Xi is C
• X 2 is N
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - Ri 0 Rn, or -OR10, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• 5 is H
• R 4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more R i2 .
• Xi is C
• X 2 is N
• Ri is OH
• R 2 is (Ci- C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - Ri 0 Rn, or -OR10, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• R 6 is H
• R4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more R12
• R12 is (Ci-C 6 ) alkyl, (Ci-C 6 ) haloalkyl, halogen, -O-aiyl, or -O-heteroaiyl optionally substituted with one or more Ri 3
• Ri 3 is (Ci-C 6 ) alkyl, (Ci-C 6
• Xi is C
• X 2 is N
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NRioRn, or -OR10, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• R6 is H
• R 4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more R12
• R12 is (Ci-C 6 ) alkyl, (Ci-C 6 ) haloalkyl, halogen, -O-aiyl, or -O-he
• Xi is C. In another embodiment, Xi is
• C and X 2 is CH.
• Xi is C, X 2 is CH and Ri is OH.
• X 1 is C, X 2 is CH, Ri is OH, and R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - R 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8 .
• X 1 is C
• X 2 is CH
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H.
• Xi is C
• X 2 is CH
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NRioRn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 ' is H.
• X 1 is C
• X 2 is CH
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, - R 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• 5 is H.
• X 1 is C
• X 2 is CH
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR10R11, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• R 6 is H
• R 4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more Ri 2 .
• X 1 is C
• X 2 is CH
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• R6 is H
• R4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more R i2
• R i2 is (Ci-C 6 ) alkyl, (Ci-C 6 ) haloalkyl, halogen, -O-aiyl, or -O-heteroaiyl optionally substituted with one or more Ri 3 .
• X 1 is C
• X 2 is CH
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR10R11, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• R 6 is H
• R 4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more Ri 2 .
• X 1 is C
• X 2 is CH
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NR 10 Rn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• R 6 is H
• R 4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more R12
• R12 is (Ci-C 6 ) alkyl, (Ci-C 6 ) haloalkyl, halogen, -O- aryl, or -O-heteroaiyl optionally substituted with one or more Ri 3
• Ri 3 is (Ci-C 6 ) alkyl, (Ci- C 6
• Xi is C
• X 2 is N
• Ri is OH
• R 2 is (Ci-C 8 ) alkyl, aryl, heteroaryl, (C 3 -C 8 ) cycloalkyl, heterocyclyl, -NRioRn, or -ORio, wherein alkyl, aryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more R 8
• R 5 is H
• R 5 > is H
• R 6 is H
• R 4 is (Ci-C 6 ) alkyl, aryl or heteroaryl optionally substituted with one or more Ri 2
• Ri 2 is (Ci-C 6 ) alkyl, (Ci-C 6 ) haloalkyl, halogen, -O-aiyl, or -O-heteroaiyl optionally substituted with one or more Ri 3 , and two Ri 3 together when on adjacent carbons form a heterocyclyl ring optional
• Non-limiting illustrative compounds of the invention include:

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Cardiology (AREA)
• Emergency Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Endocrinology (AREA)
• Hospice & Palliative Care (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Psychiatry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (20)

Applications Claiming Priority (2)

Publications (1)

Family

ID=55310894

Family Applications (1)

Country Status (22)

Cited By (19)

Families Citing this family (50)

Citations (2)

Family Cites Families (95)

• 2015
  • 2015-12-28 TW TW104144096A patent/TWI698436B/zh active
  • 2015-12-28 AR ARP150104312A patent/AR103297A1/es unknown
  • 2015-12-28 TW TW109118957A patent/TWI770525B/zh active
  • 2015-12-29 EA EA201791507A patent/EA038204B1/ru unknown
  • 2015-12-29 ES ES19207235T patent/ES3064411T3/es active Active
  • 2015-12-29 MX MX2017008604A patent/MX373788B/es active IP Right Grant
  • 2015-12-29 EP EP15832772.6A patent/EP3240791B1/en active Active
  • 2015-12-29 WO PCT/US2015/067831 patent/WO2016109515A1/en not_active Ceased
  • 2015-12-29 EP EP19207235.3A patent/EP3623372B1/en active Active
  • 2015-12-29 ES ES15832772T patent/ES2768996T3/es active Active
  • 2015-12-29 SG SG11201704897QA patent/SG11201704897QA/en unknown
  • 2015-12-29 CA CA2972797A patent/CA2972797C/en active Active
  • 2015-12-29 CN CN201580077002.3A patent/CN107406451B/zh active Active
  • 2015-12-29 KR KR1020177021230A patent/KR102581827B1/ko active Active
  • 2015-12-29 MA MA40706A patent/MA40706A1/fr unknown
  • 2015-12-29 JP JP2017535007A patent/JP6649388B2/ja active Active
  • 2015-12-29 US US14/982,127 patent/US9902728B2/en active Active
  • 2015-12-29 AU AU2015374170A patent/AU2015374170B2/en active Active
• 2017
  • 2017-06-08 IL IL252773A patent/IL252773A0/en unknown
  • 2017-06-23 CL CL2017001687A patent/CL2017001687A1/es unknown
  • 2017-06-27 MX MX2020002963A patent/MX2020002963A/es unknown
  • 2017-06-29 SA SA517381839A patent/SA517381839B1/ar unknown
  • 2017-06-29 PH PH12017501224A patent/PH12017501224A1/en unknown
  • 2017-07-12 CO CONC2017/0006997A patent/CO2017006997A2/es unknown
  • 2017-07-13 ZA ZA2017/04746A patent/ZA201704746B/en unknown
  • 2017-07-28 EC ECIEPI201749010A patent/ECSP17049010A/es unknown
• 2018
  • 2018-01-18 US US15/874,163 patent/US10377760B2/en active Active
• 2019
  • 2019-07-19 US US16/517,149 patent/US10934299B2/en active Active
• 2021
  • 2021-01-20 AU AU2021200346A patent/AU2021200346A1/en not_active Abandoned
  • 2021-02-26 US US17/186,915 patent/US12018030B2/en active Active

Patent Citations (2)

Non-Patent Citations (20)

Also Published As

Similar Documents

Legal Events